Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

On April 27, 2017, the U.S. Food and Drug Administration approved regorafenib for the treatment of patients with advanced hepatocellular carcinoma (HCC) who had previously been treated with sorafenib. Approval was based on the results of a single, randomized, placebo‐controlled trial (RESORCE) that...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelosof, Lorraine, Lemery, Steven, Casak, Sandra, Jiang, Xiaoping, Rodriguez, Lisa, Pierre, Vadryn, Bi, Youwei, Liu, Jiang, Zirkelbach, Jeanne Fourie, Patel, Anuja, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896719/
https://www.ncbi.nlm.nih.gov/pubmed/29386313
http://dx.doi.org/10.1634/theoncologist.2017-0422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896719/
https://www.ncbi.nlm.nih.gov/pubmed/29386313
http://dx.doi.org/10.1634/theoncologist.2017-0422

Ejemplares similares